Floatz logo

Neratinib Maleate

Metastatic Malignant Solid Neoplasm

National Cancer Institute (NCI)Phase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

275 Active assets in the Metastatic Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Neratinib Maleate is also rated in:

Unresectable Malignant Solid NeoplasmDormant
B
Indicative ·
58 / 100
View asset →
HER2 Gene MutationDormant
B
Indicative ·
57 / 100
View asset →
Locally Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →